InflaRx (NASDAQ:IFRX) is one of the best penny stocks under $1 to buy now. As May came to an end, InflaRx announced that its ...

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum Provided by GlobeNewswire May 27, 2025, 10:30:00 PM ...

Pyoderma Gangrenosum: Pain Identified as Reliable Patient-Reported Outcome Doug Brunk September 21, 2023 0 ...

Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with the general population, according to a cohort study. “Pyoderma gangrenosum is a ...

InflaRx has initiated a phase 3 study of vilobelimab in patients with ulcerative pyoderma gangrenosum, the company announced in a press release. The multinational, randomized, double-blind ...

"We are pleased that the first patient has been dosed in the U.S. in our pivotal Phase III study with vilobelimab for the treatment of ulcerative pyoderma gangrenosum. There are currently no ...

SPOKANE, Wash. – Ryan Becker, a Spokane resident, is battling an extremely rare skin condition known as pyoderma gangrenosum. After visits to the Mayo Clinic and Johns Hopkins, Becker has been ...